Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus

Journal of Dermatology

Volumn 41, Issue 5, 2014, Pages 418-420

  Sumida, Hayakazu ^a   Asano, Yoshihide ^a   Tamaki, Zenshiro ^a   Aozasa, Naohiko ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Toyama, Tetsuo ^a   Ichimura, Yohei ^a   Noda, Shinji ^a   Akamata, Kaname ^a   Miyazaki, Miki ^a   Kuwano, Yoshihiro ^a   Yanaba, Koichi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

B cells; interstitial lung disease; rituximab; systemic lupus erythematosus; systemic sclerosis

Indexed keywords

ANTIBODY; DNA TOPOISOMERASE; RITUXIMAB; AUTOANTIBODY; MONOCLONAL ANTIBODY; TOP1 PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MIDDLE AGED; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; B LYMPHOCYTE; BLOOD; COMPLICATION; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; B-LYMPHOCYTES; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84900009349     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12461     Document Type: Article

References (15)

1. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Tashkin DP, Elashoff R, Clements PJ, et al,. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
3. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K,. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165: 6635-6643.
4. Saito E, Fujimoto M, Hasegawa M, et al,. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-1462.
5. Smith V, Van Praet JT, Vandooren B, et al,. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69: 193-197.
6. Lafyatis R, Kissin E, York M, et al,. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60: 578-583.
7. Bosello S, De Santis M, Lama G, et al,. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
8. Daoussis D, Liossis SN, Tsamandas AC, et al,. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49: 271-280.
9. Yoo WH,. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2012; 32: 795-798.
10. Daoussis D, Liossis SN, Tsamandas AC, et al,. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30: S17-S22.
11. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF,. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67: 330-334.
12. Tokunaga M, Saito K, Kawabata D, et al,. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 470-475.
13. Merrill JT, Neuwelt CM, Wallace DJ, et al,. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
14. Tashkin DP, Elashoff R, Clements PJ, et al,. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-1034.
15. Volpe A, Ruzzenente O, Caramaschi P, et al,. Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. Rheumatol Int 2009; 29: 1073-1079.